BlackRock’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-18,582
| Closed | -$13.6K | – | 5873 |
|
|
2026
Q1 | $13.6K | Sell |
18,582
-1
| -0% | -$5 | ﹤0.01% | 5366 |
|
|
2025
Q4 | $104K | Buy |
18,583
+15,705
| +546% | +$175K | ﹤0.01% | 4897 |
|
|
2025
Q3 | $21.2K | Hold |
2,878
| – | – | ﹤0.01% | 5139 |
|
|
2025
Q2 | $21.9K | Sell |
2,878
-2,823
| -50% | -$44K | ﹤0.01% | 5132 |
|
|
2025
Q1 | $109K | Sell |
5,701
-54
| -0.9% | -$1.7K | ﹤0.01% | 4745 |
|
|
2024
Q4 | $208K | Buy |
5,755
+520
| +10% | +$14.5K | ﹤0.01% | 4612 |
|
|
2024
Q3 | $151K | Buy |
5,235
+88
| +2% | +$1.96K | ﹤0.01% | 4589 |
|
|
2024
Q2 | $132K | Buy |
5,147
+554
| +12% | +$25.2K | ﹤0.01% | 4633 |
|
|
2024
Q1 | $347K | Sell |
4,593
-19
| -0.4% | -$1.51K | ﹤0.01% | 4471 |
|
|
2023
Q4 | $475K | Buy |
4,612
+177
| +4% | +$15.9K | ﹤0.01% | 4437 |
|
|
2023
Q3 | $433K | Sell |
4,435
-65
| -1% | -$6.06K | ﹤0.01% | 4463 |
|
|
2023
Q2 | $527K | Buy |
4,500
+252
| +6% | +$31.9K | ﹤0.01% | 4466 |
|
|
2023
Q1 | $356K | Hold |
4,248
| – | – | ﹤0.01% | 4625 |
|
|
2022
Q4 | $361K | Buy |
4,248
+65
| +2% | +$4.96K | ﹤0.01% | 4694 |
|
|
2022
Q3 | $133K | Buy |
+4,183
| New | +$116K | ﹤0.01% | 5091 |
|
|
2022
Q2 | – | Sell |
-1,142
| Closed | -$56K | – | 5961 |
|
|
2022
Q1 | $56K | Sell |
1,142
-100
| -8% | -$3.99K | ﹤0.01% | 5401 |
|
|
2021
Q4 | $71K | Sell |
1,242
-432
| -26% | -$30.8K | ﹤0.01% | 5350 |
|
|
2021
Q3 | $136K | Buy |
1,674
+758
| +83% | +$59.8K | ﹤0.01% | 5069 |
|
|
2021
Q2 | $89K | Buy |
+916
| New | +$92.3K | ﹤0.01% | 5083 |
|
Other funds holding RVPH
BlackRock's RVPH Position: Q2 2026 in Review
BlackRock sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2026, closing a stake of 18,582 shares — an estimated $13.6K sold.
BlackRock first reported a position in RVPH in Q2 2021 and held it in 19 quarters. The position peaked at $527K in Q2 2023. 5 funds tracked by Wall St. Rank hold RVPH as of Q2 2026.
- BlackRock reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2026 after selling out during the quarter.
- BlackRock sold 18,582 REVIVA PHARMA HLDGS INC shares in Q2 2026, an estimated $13.6K.
- BlackRock first reported a position in REVIVA PHARMA HLDGS INC in Q2 2021 and held it in 19 quarters.
- BlackRock's REVIVA PHARMA HLDGS INC position peaked at $527K in Q2 2023.
- 5 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.